Oxford BioDynamics has secured its first pharmaceutical-company agreement for the EpiSwitch Orion platform, partnering with Johnson & Johnson on inflammatory bowel disease biomarker discovery.

Johnson & Johnson's subcutaneous EGFR/MET-targeted therapy has received FDA accelerated approval for a defined population of adults with previously treated recurrent or metastatic head and neck squamous cell carcinoma.

Jaguar LAA has acquired assets from Johnson & Johnson related to the Laminar left atrial appendage closure programme, creating a newly independent medical-device company focused on advancing the technology.

The DE STSF platform combines radiofrequency and pulsed field ablation in a single catheter, expanding treatment options for electrophysiologists managing complex cardiac arrhythmias.